Phase II open-label, global study evaluating dabrafenib in combination with trametinib in pediatric patients with BRAF V600-mutant high-grade glioma (HGG) or low-grade glioma (LGG) Meeting Abstract
| Authors: | Hargrave, D.; Witt, O.; Cohen, K.; Packer, R.; Lissat, A.; Kordes, U.; Laetsch, T. W.; Hoffman, L.; Lassaletta, A.; Gerber, N. U.; Gilheeney, S.; Holm, S.; Kramm, C.; Sumerauer, D.; Reitmann, C.; Russo, M. W.; Bouffet, E. |
| Abstract Title: | Phase II open-label, global study evaluating dabrafenib in combination with trametinib in pediatric patients with BRAF V600-mutant high-grade glioma (HGG) or low-grade glioma (LGG) |
| Meeting Title: | 43rd ESMO Congress (ESMO 2018) |
| Journal Title: | Annals of Oncology |
| Volume: | 29 |
| Issue: | Suppl. 8 |
| Meeting Dates: | 2018 Oct 19-23 |
| Meeting Location: | Munich, Germany |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2018-10-01 |
| Start Page: | mdy273.395 |
| Language: | English |
| ACCESSION: | WOS:000459277300398 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdy273.395 |
| Notes: | Meeting Abstract: 407TiP -- Appears on page viii132 of the abstract book -- Source: Wos |
